journal
MENU ▼
Read by QxMD icon Read
search

Neuro-oncology

journal
https://www.readbyqxmd.com/read/29452419/temozolomide-associated-hypermutation-in-gliomas
#1
Serah Choi, Yao Yu, Matthew R Grimmer, Michael Wahl, Susan M Chang, Joseph F Costello
Low-grade gliomas cause considerable morbidity and most will recur after initial therapy. At recurrence, low-grade gliomas can undergo transformation to high-grade gliomas (grade III or grade IV), which are associated with worse prognosis. Temozolomide (TMZ) provides survival benefit in patients with glioblastomas (GBMs) but its value in patients with low-grade gliomas is less clear. A subset of TMZ-treated, IDH-mutant, low-grade astrocytomas recur as more malignant tumors with thousands of de novo, coding mutations bearing a signature of TMZ-induced hypermutation...
February 14, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29438510/diagnostic-accuracy-of-2-hydroxyglutarate-magnetic-resonance-spectroscopy-in-newly-diagnosed-brain-mass-and-suspected-recurrent-gliomas
#2
Min Zhou, Yue Zhou, Huijun Liao, Benjamin C Rowland, Xiangquan Kong, Nils D Arvold, David A Reardon, Patrick Y Wen, Alexander P Lin, Raymond Y Huang
Background: Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the diagnostic accuracy of 2HG single-voxel spectroscopy (SVS) and chemical shift imaging (CSI) in both newly-diagnosed and post-treatment settings. Methods: Long-TE (97 ms) SVS and CSI were acquired in 85 subjects, including a discovery cohort of 39 patients who had postoperative residual or recurrent glioma with confirmed IDH-mutation status and 6 normal volunteers, a prospective preoperative validation cohort of 24 patients with newly-diagnosed brain mass, and a prospective recurrent-lesion validation cohort of 16 previously-treated IDH-mutant glioma patients with suspected tumor recurrence...
February 9, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29438500/diffusion-radiomics-as-a-diagnostic-model-for-atypical-manifestation-of-primary-central-nervous-system-lymphoma-development-and-multicenter-external-validation
#3
Daesung Kang, Ji Eun Park, Young-Hoon Kim, Jeong Hoon Kim, Joo Young Oh, Jungyoun Kim, Yikyung Kim, Sung Tae Kim, Ho Sung Kim
Background: Radiomics is a rapidly growing field in neuro-oncology, but studies have been limited to conventional MRI and external validation is critically lacking. We evaluated technical feasibility, diagnostic performance, and generalizability of a diffusion radiomics model for identifying atypical primary central nervous system lymphoma (PCNSL) mimicking glioblastoma. Methods: Total 1618 radiomics features were extracted from diffusion and conventional MRI from 112 patients (training set, 70 glioblastomas and 42 PCNSLs)...
February 9, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29432618/a-new-practical-and-versatile-mouse-model-of-proneural-glioblastoma
#4
Roger Abounader
No abstract text is available yet for this article.
February 8, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29432615/glioma-through-the-looking-glass-molecular-evolution-of-diffuse-gliomas-and-the-glioma-longitudinal-analysis-consortium
#5
Kenneth Aldape, Samirkumar B Amin, David M Ashley, Jill S Barnholtz-Sloan, Amanda J Bates, Rameen Beroukhim, Christoph Bock, Daniel J Brat, Elizabeth B Claus, Joseph F Costello, John F de Groot, Gaetano Finocchiaro, Pim J French, Hui K Gan, Brent Griffith, Christel C Herold-Mende, Craig Horbinski, Antonio Iavarone, Steven N Kalkanis, Konstantina Karabatsou, Hoon Kim, Mathilde C M Kouwenhoven, Kerrie L McDonald, Hrvoje Miletic, Do-Hyun Nam, Ho Keung Ng, Simone P Niclou, Houtan Noushmehr, Ryan Ormond, Laila M Poisson, Guido Reifenberger, Federico Roncaroli, Jason K Sa, Peter A E Sillevis Smitt, Marion Smits, Camila F Souza, Ghazaleh Tabatabai, Erwin G Van Meir, Roel G W Verhaak, Colin Watts, Pieter Wesseling, Adelheid Woehrer, W K Alfred Yung, Christine Jungk, Ann-Christin Hau, Eric van Dyck, Bart A Westerman, Julia Yin, Olajide Abiola, Nikolaj Zeps, Sean Grimmond, Michael Buckland, Mustafa Khasraw, Erik P Sulman, Andrea M Muscat, Lucy Stead
Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas (TCGA) and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal AnalySiS Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas...
February 8, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29432597/identification-of-novel-recurrent-etv6-igh-fusions-in-primary-central-nervous-system-lymphoma
#6
Aurélie Bruno, Karim Labreche, Maïlys Daniau, Blandine Boisselier, Guillaume Gauchotte, Louis Royer-Perron, Amithys Rahimian, Frédéric Lemoine, Pierre de la Grange, Justine Guégan, Franck Bielle, Marc Polivka, Clovis Adam, David Meyronet, Dominique Figarella-Branger, Chiara Villa, Fabrice Chrétien, Sandrine Eimer, Frédéric Davi, Audrey Rousseau, Caroline Houillier, Carole Soussain, Karima Mokhtari, Khê Hoang-Xuan, Agusti Alentorn
Background: Primary central nervous system lymphoma (PCNSL) represents a particular entity within non-Hodgkin lymphomas and is associated with poor outcome. The present study addresses the potential clinical relevance of chimeric transcripts in PCSNL discovered by using RNA-sequencing (RNA-Seq). Methods: Seventy-two immunocompetent and newly diagnosed PCNSL cases were included in the present study. Among them, six were analyzed by RNA-seq to detect new potential fusion transcripts...
February 8, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29432558/models-of-epigenetic-age-capture-patterns-of-dna-methylation-in-glioma-associated-with-molecular-subtype-survival-and-recurrence
#7
Peter Liao, Quinn T Ostrom, Lindsay Stetson, Jill S Barnholtz-Sloan
Background: Models of epigenetic aging (epigenetic clocks) have been implicated as potentially useful markers for cancer risk and prognosis. Using two previously published methods for modeling epigenetic age, Horvath's clock and epiTOC, we investigated epigenetic aging patterns related to WHO grade and molecular subtype as well as associations of epigenetic aging with glioma survival and recurrence. Methods: Epigenetic ages were calculated using Horvath's clock and epiTOC on 516 lower grade glioma and 141 glioblastoma cases along with 136 non-tumor (normal) brain samples...
February 8, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29415215/hypoxia-activated-evofosfamide-for-treatment-of-recurrent-bevacizumab-refractory-glioblastoma-a-phase-i-surgical-study
#8
Andrew Brenner, Richard Zuniga, Jessica D Sun, John Floyd, Charles P Hart, Stew Kroll, Lisa Fichtel, David Cavazos, Laura Caflisch, Aleksandra Gruslova, Alessia Lodi, Stephano Tiziani
Background: Antiangiogenic therapy is known to induce a greater degree of hypoxia, including in glioblastoma (GBM). Evofosfamide (Evo) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramide mustard. We assessed the safety, tolerability, preliminary efficacy, and biomarkers of Evo plus bevacizumab (Bev) in Bev refractory glioblastoma. Methods: Twenty-eight patients with Bev refractory GBM were enrolled in a dose escalation study receiving from 240mg/m2 (cohort 1) to 670mg/m2 (cohort 4) of Evo every 2 weeks in combination with Bev...
February 5, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29409029/the-characteristics-of-76-atypical-neurofibromas-as-precursors-to-neurofibromatosis-1-associated-malignant-peripheral-nerve-sheath-tumors
#9
Christine S Higham, Eva Dombi, Aljosja Rogiers, Sucharita Bhaumik, Steven Pans, Steve E J Connor, Markku Miettinen, Raf Sciot, Roberto Tirabosco, Hilde Brems, Andrea Baldwin, Eric Legius, Brigitte C Widemann, Rosalie E Ferner
Background: Neurofibromatosis 1 (NF1) leads to the development of benign and malignant peripheral nerve sheath tumors (MPNST). MPNST have been described to develop in pre-existing benign plexiform neurofibromas (PN) and have a poor prognosis. Atypical neurofibromas (ANF) were recently described as precursor lesions for MPNST, making early detection and management of ANF a possible strategy to prevent MPNST. We aimed to clinically characterize ANF and identify management approaches. Methods: We analyzed clinical, imaging, and pathology findings of all patients with NF1 and ANF at three institutions...
February 2, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29409010/reactive-species-balance-via-gtp-cyclohydrolase-i-regulates-glioblastoma-growth-and-tumor-initiating-cell-maintenance
#10
Anh Nhat Tran, Kiera Walker, David G Harrison, Wei Chen, James Mobley, Lauren Hocevar, James R Hackney, Randee S Sedaka, Jennifer S Pollock, Matthew S Goldberg, Dolores Hambardzumyan, Sara J Cooper, Yancey Gillespie, Anita B Hjelmeland
Background: Depending on the level, differentiation state, and tumor stage, reactive nitrogen and oxygen species inhibit or increase cancer growth and tumor initiating cell maintenance. The rate limiting enzyme in a pathway that can regulate reactive species production but has not been thoroughly investigated in glioblastoma (GBM; grade IV astrocytoma) is GTP cyclohydrolase 1 (GCH1). We sought to define the role of GCH1 in the regulation of GBM growth and brain tumor initiating cell maintenance...
February 2, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29409008/targeted-next-generation-sequencing-for-differential-diagnosis-of-neurofibromatosis-type-2-schwannomatosis-and-meningiomatosis
#11
Camille Louvrier, Eric Pasmant, Audrey Briand-Suleau, Joëlle Cohen, Patrick Nitschké, Juliette Nectoux, Lucie Orhant, Cécile Zordan, Cyril Goizet, Stéphane Goutagny, Dominique Lallemand, Michel Vidaud, Dominique Vidaud, Michel Kalamarides, Béatrice Parfait
Background: Clinical overlap between neurofibromatosis type 2 (NF2), schwannomatosis, and meningiomatosis can make clinical diagnosis difficult. Hence, molecular investigation of germline and tumor tissues may improve the diagnosis. Methods: We present the targeted next generation sequencing (NGS) of NF2, SMARCB1, LZTR1, SMARCE1, and SUFU tumor suppressor genes, using an amplicon-based approach. We analyzed blood DNA from a cohort of 196 patients, including patients with: NF2 (N=79), schwannomatosis (N=40), meningiomatosis (N=12), and no clearly established diagnosis (N=65)...
February 2, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29401256/syk-inhibition-blocks-proliferation-and-migration-of-glioma-cells-and-modifies-the-tumor-microenvironment
#12
Gerald Moncayo, Michal Grzmil, Tatiana Smirnova, Pawel Zmarz, Roland M Huber, Debby Hynx, Hubertus Kohler, Yuhua Wang, Hans-Rudolf Hotz, Nancy E Hynes, Georg Keller, Stephan Frank, Adrian Merlo, Brian A Hemmings
Background: Glioblastoma (GBM) is one of the most aggressive human brain tumors with a median survival of 15-18 months. There is a desperate need to find novel therapeutic targets. Various receptor protein kinases have been identified as potential targets; however, response rates in clinical studies have been somewhat disappointing. Targeting the Spleen Tyrosine Kinase (SYK), which acts downstream of a range of oncogenic receptors, may therefore show more promising results. Methods: Kinase expression of brain tumor samples including GBM and low-grade tumors were compared to normal brain and normal human astrocytes (NHA) by microarray analysis...
February 1, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29390139/maintaining-quality-of-life-near-the-end-of-life-hospice-in-neuro-oncology
#13
Tobias Walbert
No abstract text is available yet for this article.
January 30, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29373718/the-aberrant-splicing-of-baf45d-links-splicing-regulation-and-transcription-in-glioblastoma
#14
Guillermo Aldave, Marisol Gonzalez-Huarriz, Angel Rubio, Juan Pablo Romero, Datta Ravi, Belén Miñana, Mar Cuadrado-Tejedor, Ana García-Osta, Roeland Verhaak, Enric Xipell, Naiara Martinez-Vélez, Arlet Acanda de la Rocha, Montserrat Puigdelloses, Marc García-Moure, Miguel Marigil, Jaime Gállego Pérez-Larraya, Oskar Marín-Bejar, Maite Huarte, Maria Stella Carro, Roberto Ferrarese, Cristobal Belda-Iniesta, Angel Ayuso, Ricardo Prat-Acín, Fernando Pastor, Ricardo Díez-Valle, Sonia Tejada, Marta M Alonso
Background: Glioblastoma, the most aggressive primary brain tumor, is a genetically heterogeneous tumor. Alternative spicing (AS) plays a key role in numerous pathologies, including cancer. The objective of our study was to determine whether aberrant AS could play a role in the malignant phenotype of glioma and to understand the mechanism underlying its aberrant regulation. Methods: We obtained surgical samples from patients with glioblastoma who underwent 5-aminolevulinic fluorescence-guided surgery...
January 24, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29315410/standard-chemoradiation-in-combination-with-vegf-targeted-therapy-for-glioblastoma-results-in-progressive-gray-and-white-matter-volume-loss
#15
Morgan L Prust, Kourosh Jafari-Khouzani, Jayashree Kalpathy-Cramer, Pavlina Polaskova, Tracy T Batchelor, Elizabeth R Gerstner, Jorg Dietrich
No abstract text is available yet for this article.
January 5, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29309676/survival-impact-of-postoperative-radiotherapy-timing-in-pediatric-and-adolescent-medulloblastoma
#16
Alexander L Chin, Everett J Moding, Sarah S Donaldson, Iris C Gibbs, Scott G Soltys, Susan M Hiniker, Erqi L Pollom
Background: Radiation therapy (RT) remains a critical component of multimodality treatment for medulloblastoma. Traditionally, clinicians strive to start RT within 4-5 weeks of surgery, but the optimal timing after surgery remains unclear. Methods: Using the National Cancer Database, we identified pediatric and adolescent patients with medulloblastoma treated with curative-intent surgery, RT, and chemotherapy. Factors associated with early or delayed RT were identified using Pearson chi-squared tests...
January 4, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29304249/extent-of-surgery-in-low-grade-gliomas-an-old-question-in-a-new-context
#17
Roberta Rudà, Riccardo Soffietti
No abstract text is available yet for this article.
January 3, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29304234/corrigendum
#18
(no author information available yet)
No abstract text is available yet for this article.
January 3, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29294092/protein-phosphatase-2a-inhibition-enhances-radiation-sensitivity-and-reduces-tumor-growth-in-chordoma
#19
Shuyu Hao, Hua Song, Wei Zhang, Ashlee Seldomridge, Jinkyu Jung, Amber J Giles, Marsha-Kay Hutchinson, Xiaoyu Cao, Nicole Colwell, Adrian Lita, Mioara Larion, Dragan Maric, Mones Abu-Asab, Martha Quezado, Tamalee Kramp, Kevin Camphausen, Zhengping Zhuang, Mark R Gilbert, Deric M Park
Background: Standard therapy for chordoma consists of surgical resection followed by high-dose irradiation. Protein phosphatase 2A (PP2A) is an ubiquitously expressed serine/threonine phosphatase involved in signal transduction, cell cycle progression, cell differentiation, and DNA repair. LB100 is a small molecule inhibitor of PP2A designed to sensitize cancer cells to DNA damage from irradiation and chemotherapy. A recently completed phase I trial of LB100 in solid tumors demonstrated its safety...
December 23, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29294080/regulation-of-bioenergetics-through-dual-inhibition-of-aldehyde-dehydrogenase-and-mitochondrial-complex-i-suppresses-glioblastoma-tumorspheres
#20
Junseong Park, Jin-Kyoung Shim, Joon Hee Kang, Junjeong Choi, Jong Hee Chang, Soo-Youl Kim, Seok-Gu Kang
Background: Targeted approaches for treating glioblastoma (GBM) attempted to date have consistently failed, highlighting the imperative for treatment strategies that operate on different mechanistic principles. Bioenergetics deprivation has emerged as an effective therapeutic approach for various tumors. We have previously found that cancer cells preferentially utilize cytosolic NADH supplied by aldehyde dehydrogenase (ALDH) for ATP production through oxidative phosphorylation (OxPhos)...
December 23, 2017: Neuro-oncology
journal
journal
34661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"